Roche applies Halozyme's Enhanze to biological drugs
To make it easier for its injectable large molecules to pass through the skin and into the body, Roche has licensed from recombinant human enzyme producer Halozyme Therapeutics exclusive rights to apply the latter's Enhanze delivery system to the former's biological medicines.
- Drug Delivery
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.